Screening for brain metastases in patients with stage III non–small-cell lung cancer, magnetic resonance imaging or computed tomography? A prospective study

Schoenmaekers, Janna; Hofman, Paul; Bootsma, Gerben; Westenend, Marcel; Booij, M. de; Schreurs, Wendy; Houben, Ruud; Ruysscher, Dirk De; Dingemans, Anne‐Marie C.; Hendriks, Lizza

doi:10.1016/j.ejca.2019.04.017

Cited by 23 publications

(18 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, most specialized centers routinely perform brain imaging as a part of initial staging in patients considered for curative approaches. Since 18 F-FDG PET-CT has low diagnostic accuracy for brain metastases, routine brain imaging includes CT or MRI; the latter identifying additional 4.7% of patients with brain dissemination compared to CT (20).…”

Section: Brain Imagingmentioning

confidence: 99%

Concurrent chemoradiotherapy for stage III non-small-cell lung cancer: recent progress and future perspectives (a narrative review)

Łazar-Poniatowska

Bandura

Dziadziuszko

et al. 2021

Transl Lung Cancer Res

View full text Add to dashboard Cite

show abstract

Section: Brain Imagingmentioning

confidence: 99%

Concurrent chemoradiotherapy for stage III non-small-cell lung cancer: recent progress and future perspectives (a narrative review)

Łazar-Poniatowska

Bandura

Dziadziuszko

et al. 2021

Transl Lung Cancer Res

View full text Add to dashboard Cite

show abstract

“…For imaging, the main differences were that in the survey only two-thirds of stage III NSCLC and 50% of driver altered patients were screened for BM, and only half of responders used MRI as the screening method [4]. However, in stage III NSCLC (with a risk of approximately 20% asymptomatic baseline BM [19]), MRI detects BM in 4.7% of neurologically asymptomatic patients, after a negative contrast-enhanced brain CT [20]. Open questions are whether BM screening improves QoL and/or survival and which stages should be screened.…”

Section: Bm Screening: Patients and Techniquesmentioning

confidence: 99%

Current challenges in the management of nonsmall cell lung cancer brain metastases

2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Short echo times have been shown to be crucial in improving the quality of lung proton MRIs ( 14 ). The pointwise encoding time reduction with radial acquisition (PETRA) sequence is a noiseless prototype hybrid approach to ultrashort-echo-time three-dimensional imaging ( 15 , 16 ).…”

Section: Introductionmentioning

confidence: 99%

The Value of PETRA in Pulmonary Nodules of <3 cm Among Patients With Lung Cancer

et al. 2021

View full text Add to dashboard Cite

ObjectiveThis study aimed to evaluate the visibility of different subgroups of lung nodules of <3 cm using the pointwise encoding time reduction with radial acquisition (PETRA) sequence on 3T magnetic resonance imaging (MRI) in comparison with that obtained using low-dose computed tomography (LDCT).MethodsThe appropriate detection rate was calculated for each of the different subgroups of lung nodules of <3 cm. The mean diameter of each detected nodule was determined. The detection rates and diameters of the lung nodules detected by MRI with the PETRA sequence were compared with those detected by computed tomography (CT). The sensitivity of detection for the different subgroups of pulmonary nodules was determined based on the location, size, type of nodules and morphologic characteristics. Agreement of nodule characteristics between CT and MRI were assessed by intraclass correlation coefficient (ICC) and Kappa test.ResultsThe CT scans detected 256 lung nodules, comprising 99 solid nodules (SNs) and 157 subsolid nodules with a mean nodule diameter of 8.3 mm. For the SNs, the MRI detected 30/47 nodules of <6 mm in diameter and 52/52 nodules of ≥6 mm in diameter. For the subsolid nodules, the MRI detected 30/51 nodules of <6 mm in diameter and 102/106 nodules of ≥6 mm in diameter. The PETRA sequence returned a high detection rate (84%). The detection rates of SN, ground glass nodules, and PSN were 82%, 72%, and 94%, respectively. For nodules with a diameter of >6 mm, the sensitivity of the PETRA sequence reached 97%, with a higher rate for nodules located in the upper lung fields than those in the middle and lower lung fields. Strong agreement was found between the CT and PETRA results (correlation coefficients = 0.97).ConclusionThe PETRA technique had high sensitivity for different type of nodule detection and enabled accurate assessment of their diameter and morphologic characteristics. It may be an effective alternative to CT as a tool for screening and follow up pulmonary nodules.

show abstract

Screening for brain metastases in patients with stage III non–small-cell lung cancer, magnetic resonance imaging or computed tomography? A prospective study

Abstract: Screening for brain metastases in patients with stage III non-small-cell lung cancer, magnetic resonance imaging or computed tomography? A prospective study.

Cited by 23 publications

References 32 publications

Concurrent chemoradiotherapy for stage III non-small-cell lung cancer: recent progress and future perspectives (a narrative review)

Concurrent chemoradiotherapy for stage III non-small-cell lung cancer: recent progress and future perspectives (a narrative review)

Current challenges in the management of nonsmall cell lung cancer brain metastases

The Value of PETRA in Pulmonary Nodules of <3 cm Among Patients With Lung Cancer

Contact Info

Product

Resources

About